The correlations between CXCL12, CXCR4, EAAT1 and GS in malignant pleural mesothelioma, and CXCL12 regulates cell invasion and migration via CXCR4/EAA1/GS pathway

Author names and affiliations
Shuo Li1, 2,*, Tong Li1,* #, Qiang Lin3,*, Debing Shi4, Haishi Zheng1, Jin Zhang5, Hui Li1, Shengcai Hou1, Orli Kadoch6, Yilin Yang6 and Zhidong Xu6

1Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, PRC
2Department of Thoracic Surgery, The Affiliated Hospital of QingDao University, QingDao, 266000, PRC
3Shanghai Bio-innovation Biotechnology Co., Ltd., National Science Park of Fudan University, Shanghai, PRC
4Department of Oncology, Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, PRC
5Surgical Intensive Care Unit, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, PRC
6Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

*These authors contributed equally to this work.
#Correspondence to:
Tong Li, Thoracic Surgery Department, Beijing Chao-Yang Hospital, Capital Medical University, No. 8, Gongtinan Road, Chao-Yang district, Beijing, 100020, PRC, Phone: 86-010-85231454, Fax: 86-010-85231165, E-mail: li_tong_724@sina.com

Simple Summary:
CXCL12/CXCR4 axis is known closely related to tumors such as malignant pleural mesothelioma (MPM). Since we have recently found EAAT1/GS (Excitatory amino acid transporter 1/Glutamine synthetase) were highly-expressed in MPM tissues. This study aims to analyze the correlations between them in MPM and normal tissues, and to elucidate the mechanism of CXCR4/EAA1/GS pathway in CXCL12 regulating invasion and migration. We confirmed significant correlations between CXCL12 and CXCR4, CXCL12 and EAAT1, CXCR4 and EAAT1, CXCR4 and GS, EAAT1 and GS in MPM samples. CXCL12 upregulated CXCR4, EAAT1 and GS expression in H2052 cells. The EAAT1 and GS expression upregulated or not by CXCL12 were decreased by CXCR4 and EAAT1 knockdown. CXCR4 antagonist AMD3100 and EAAT1 antagonist TFB-TBOA also resulted in the same effects. CXCL12 promoted cell invasion and migration. CXCR4 and EAAT1 knockdown suppressed all these functions, suggesting that CXCL12 regulated the invasion and migration through CXCR4/EAA1/GS pathway in H2052 cells.

Abstract:

Purpose: To elucidate the mechanism of CXCR4/EAA1/GS pathway in CXCL12 regulating invasion and migration in malignant pleural mesothelioma (MPM).

Methods: Immunohistochemistry for CXCL12, CXCR4, EAA1 and GS stainings and correlation analysis between them were conducted in MPM and normal tissues. Western blot and real-time PCR were performed to examine the CXCR4, EAA1 and GS expression in H2052 cells. Wound healing and transwell assay were applied to determine the cell migration and invasion. MTT was utilized to assess cell viability.

Results: CXCL12, CXCR4, EAA1 and GS were highly expressed in MPM tissues and correlated with each other. CXCL12 upregulated both in protein and mRNA levels of CXCR4, EAA1 and GS in H2052 cells. The EAA1 and GS expression upregulated or not by CXCL12 were decreased by CXCR4 and EAA1 knockdown. CXCR4 antagonist AMD3100 and EAA1 antagonist TFB-TBOA also resulted in the same effects as CXCR4 and EAA1 knockdown, respectively. CXCL12 promoted cell invasion and migration and increased the Matrix metalloproteinase 9 (MMP9) mRNA level. CXCR4 and EAA1 knockdown suppressed all these functions. Furthermore, CXCL12 promoted H2052 cells growth in nude mice, both AMD3100 and TFB-TBOA inhibited this promotion.
Conclusions: CXCL12 regulated the invasion and migration through CXCR4/EAAT1/GS pathway in H2052 cells.

**Keywords:** Malignant pleural mesothelioma; CXCL12/CXCR4; EAAT1; Glutamine synthetase; Invasion; Migration

1. Introduction

Malignant pleural mesothelioma (MPM) is a relatively rare and aggressive cancer, originating from mesothelial surfaces of the pleural lining. The prognosis of MPM is poor for decades due to its nonspecific clinical manifestations and the relatively late diagnosis [1]. Treatments for MPM in the past rarely extend patients survival beyond 12 months [2,3]. However, recent studies have elucidated genetic alterations in mesothelioma. Some genes have been found to be significantly expressed in MPM, such as BAP1, NF2, TP53, SETD2, SMARCC1, PBRM1, SF3B1 and TRAF7 [4-7]. Pastorino et al. [8] reported that a subset of MPM patients who were not aware of asbestos exposure and carried pathogenic germline mutations of BAP1 had significantly improved survival. Nevertheless, recent clinical trials targeting molecular pathways have failed to significantly improve the prognosis of MPM [9]. Therefore, a better understanding of the cytogenetic and molecular pathogenesis of MPM is still needed to develop effective therapeutic approaches for the MPM patients [10-12].

Chemokines are a class of chemotactic cytokines that are categorized based on the positioning of well-conserved N-terminal cysteine residues and classified as C, CC, CXC, CX3C chemokines. Chemokines play a critical role in many biological processes, including hematopoiesis, immune cell trafficking and stem and progenitor cell mobility by activating their corresponding chemokine receptors, which belong to the rhodopsin-like seven transmembrane G protein-coupled receptor (GPCR) family [13,14]. Among these receptors, CXCR4, a kind of very important receptor, is widely expressed in various types of tissues, where it plays a central role in development-related processes [15,16] and tumor metastasis. CXCR4 is the specific chemokine receptor which can interact with the chemokine
CXCL12, also known as Stromal-Derived Factor-1 (SDF-1) ligand [17]. CXCL12 was expressed in breast tumor, brain tumor and colorectal cancer tissues [18-20], etc. and also usually expressed in fibroblasts and endothelial cells [21,22] or produced by stromal cells of lymph nodes, lung, liver, and bone marrow, which were the most common sites for metastasis [23]. CXCL12/CXCR4 axis is also a key factor in the tumor development, metastasis and cross-talking between tumor cells and their microenvironment of various malignancies [24,25]. This axis not only promotes the survival and proliferation of cancer cells but also attracts the CXCR4-expressed tumor tissue/organ-specific metastasis [26,27]. In addition, previous work suggests that CXCL12 and CXCR4 are involved in MPM tumorigenesis [28,29].

Glutamate (Glu) is an important excitatory neurotransmitter of mammalian central nervous system (CNS) [30]. The presynaptic concentration of Glu in human CNS is regulated by Glutamate transporters (excitatory amino acid transporters, EAATs) [31], which utilize the transmembrane gradients of Na⁺, K⁺, and H⁺ as a driving force to uptake glutamate from extracellular space into cells [32], and subsequently converted into glutamine by glutamine synthetase (GS), which is a glia-specific enzyme [33,34], and transported back to the neurons for recycling into glutamate. To date, five EAATs (EAAT1 ~ 5) have been characterized [35,36]. Evidence has suggested that EAATs play a critical role in maintaining extracellular glutamate homeostasis and regulating glutamate neurotransmission [37-39]. Among these EAATs, EAAT1 is a ubiquitous subtype. GS is the only key enzyme that is capable of de novo synthesis of glutamine and also functions to detoxify glutamate and ammonia [40], which is involved in nitrogen metabolism [41] and in the metabolic pathway of glutamate [42]. Nevertheless, there is evidence showed that the glutamatergic system may also have an important role in non-neuronal tissues, such as in cancer biology [31].

CXCL12/CXCR4 axis is known closely related to tumors such as malignant pleural mesothelioma (MPM). Our previous research showed that CXCL12 was a functional activation factor of Akt downstream pathways and could induce cell proliferation in several mesothelioma cell lines and the CXCL12/CXCR4 antagonist AMD3100 blocked these
effects [43]. Moreover, we also found that EAAT1 was highly-expressed in most of human MPM cell lines and some MPM tissues. The degree of EAAT1 staining by IHC was correlated with pathological type but inversely correlated with the survival time of patients [44]. However, no reports described the functions of EAAT1 in MPM and whether CXCL12 could regulate cell invasion and migration via CXCR4/EAA1/GS pathway is still unknown.

Therefore, in the present study, we have included more clinical samples and completely examined the expression of CXCL12, CXCR4, EAAT1 and GS in normal pleura and MPM samples, and analyze the correlations between them. Additionally, In vitro experimental studies were designed to investigate the mechanism of CXCR4/EAA1/GS pathway in CXCL12 regulating invasion and migration in malignant pleural mesothelioma (MPM).

2. Results

2.1. Immunohistochemistry (IHC) staining of CXCL12, CXCR4, EAAT1 and GS in normal pleura and MPM samples

The positive or negative results of CXCL12, CXCR4, EAAT1, GS and HE staining in MPM samples in the tissue microarray sections were shown in Figure. 1 and Table 1 and 2. In MPM samples, the percentages of strong positive (++) in CXCL12, CXCR4, EAAT1 and GS staining were 7.3%, 39.1%, 23.1% and 8.6%, respectively and the strong positive ratio in CXCR4 staining was the highest. While the percentages of negative (−) in CXCL12, CXCR4, EAAT1 and GS staining were 22%, 2.4%, 2.7% and 8.6%, respectively and the negative ratio in CXCR4 staining was the lowest. In normal pleura samples, the percentages of strong positive (++) in CXCL12, CXCR4, EAAT1 and GS staining were 22%, 2.4%, 2.7% and 8.6%, respectively and the negative ratio in CXCR4 staining was the lowest. In normal pleura samples, the percentages of strong positive (++) in CXCL12, CXCR4, EAAT1 and GS staining were negative (−). While the percentages of negative (−) in CXCL12 staining is higher (60%) than CXCR4 (30%), EAAT1 (50%) and GS (20%) staining, respectively.
**Figure 1.** IHC staining of CXCL12, CXCR4, EAAT1, GS and HE staining in mesothelioma and normal pleura samples (200×). a-d: IHC staining of CXCL12. a: Normal pleura sample. b-d: Mesothelioma samples. b: Negative. c: Moderate. d: Strong. e-h: IHC staining of CXCR4. e: Normal pleura sample. f-h: Mesothelioma samples. f: Negative. g: Moderate. h: Strong. i-l: IHC staining of EAAT1. i: Normal pleura sample. j-l: Mesothelioma samples. j: Negative. k: Moderate. l: Strong. m-p: IHC staining of GS. m: Normal pleura sample. n-p: Mesothelioma samples. n: Negative. o: Moderate. p: Strong. q, r: HE staining. q: Normal pleura sample. r: Mesothelioma samples. s-w: IHC staining in one mesothelioma sample. s: IHC staining of CXCL12. t: IHC staining of CXCR4. u: IHC staining of EAAT1. v: IHC staining of GS. w: HE staining.

**Table 1.** Characteristics of primary human MPM and normal pleura samples

| Number of the sample | IHC of anti-CXCL12 | IHC of anti-CXCR4 | IHC of anti-EAAT1 | IHC of anti-GS |
|----------------------|---------------------|-------------------|-------------------|----------------|
| N233                 | -                   | -                 | -                 | +              |
| N237                 | +                   | ++                | +                 | +              |
| T237                 | +                   | +                 | ++                | +              |
| T241                 | +                   | +                 | ++                | ++             |
| N242                 | -                   | +                 | +                 | +              |
| T242                 | ++                  | +++               | ++                | +              |
| N244                 | +                   | +                 | ++                | +              |
| T246                 | ++                  | +++               | +++               | ++             |
| T264                 | +                   | +                 | +                 | ++             |
| T300                 | +                   | +                 | ++                | ND             |
| T324                 | -                   | +                 | ++                | +              |
|    | N331 | T331 | T370 | T374 | T383 | T392 | T394 | T396 | T401 | T410 | T416 | T439 | T453 | N472 | T472 | T473 | T484 | T501 | T514 | T660 | T696 |
|----|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|    | +    | +    | -    | -    | -    | +    | -    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| N331 | +    | +    | -    | -    | -    | +    | -    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T331 | -    | +    | +    | +    | -    | +    | -    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T370 | +++  | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T374 | ++   | +++  | +++  | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   |
| T383 | -    | +    | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   |
| T392 | ++   | ++   | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T394 | ++   | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T396 | +    | +    | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T401 | -    | +    | -    | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   |
| T410 | ++   | +++  | +    | +    | ++   | ++   | ++   | ++   | ++   | ++   | ++   | ++   | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T416 | +    | ++   | +++  | ++   | ++   | ++   | ++   | ++   | ++   | ++   | ++   | ++   | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T439 | -    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T453 | ++   | +++  | +++  | ++   | ++   | ++   | ++   | ++   | ++   | ++   | ++   | ++   | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| N472 | +    | +    | -    | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T472 | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T473 | ++   | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T484 | ++   | +++  | +++  | +++  | +++  | +++  | +++  | +++  | +++  | +++  | +++  | +++  | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T501 | ++   | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T514 | ++   | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    | +    | -    | +    | -    | +    | -    | +    | +    | +    | +    | +    |
| T660 | ++   | +++  | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   |
| T696 | +++  | +++  | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   | ND   |
|   | T713 | T737 | N745 | T773 | N775 | T775 | N777 | T777 | T795 | T809 | T813 | T829 | T839 | T858 | T862 | N869 | T869 | T905 | T936 |
|---|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|   | +++  | +++  | +++  | +++  | +++  | ++   | +    | ++   | +    | +++  | ++   | +    | +    | +    | +    | +    | +    | +    | +    |
|   | +    | +    | ++   | +    | -    | --   | -    | +    | +    | -    | +    | +    | -    | -    | +    | +    | +    | +    |
|   | -    | +    | ++   | +    | -    | ++   | +    | ++   | +    | -    | +    | +    | -    | -    | +    | +    | +    | +    |
|   | +    | +    | +++  | ++   | +    | ++   | +    | ++   | +    | -    | +    | +    | +    | +    | +    | +    | +    | +    |
|   | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    | +    |
| N | normal tissue; T, tumor tissue; IHC, immunohistochemistry; -, no stain; +, weak stain; ++, moderate stain; ++++, strong stain; ND, not done. |
**Table 2.** Positive and negative staining for CXCL12, CXCR4, EAAT1 and GS in MPM and normal pleura samples

|                  | Number (%) | Number (%) | Number (%) | Number (%) |
|------------------|------------|------------|------------|------------|
|                  | -  | +  | ++ | +++ |
| **CXCL12**       |    |    |    |    |
| MPM samples      | 9(22.0%) | 16(39.0%) | 13(31.7%) | 3(7.3%)    |
| Normal pleura    | 6(60.0%) | 3(30.0%)  | 1(10.0%)  | 0(0%)      |
| **CXCR4**        |    |    |    |    |
| MPM samples      | 1(2.4%)  | 18(43.9%) | 6(14.6%)  | 16(39.1%)  |
| Normal pleura    | 3(30.0%) | 6(60.0%)  | 1(10.0%)  | 0(0%)      |
| **EAAT1**        |    |    |    |    |
| MPM samples      | 1(2.7%)  | 12(30.8%) | 15(40.5%) | 9(23.1%)   |
| Normal pleura    | 5(50%)   | 3(30%)    | 2(20%)    | 0(0%)      |
The overall positive ratios of CXCL12, CXCR4, EAAT1 and GS staining were 78%, 97.6%, 97.3% and 91.4% in MPM samples, respectively and were 40%, 70%, 50.0% and 80.0% in normal pleura samples, respectively. Multiple correlation analysis were shown in Table 3, CXCL12 was strongly correlated with both CXCR4 ($R^2 = 0.8590, p < 0.01$) and EAAT1 ($R^2 = 0.6409, p < 0.01$) and CXCR4 was strongly correlated with EAAT1 ($R^2 = 0.6311, p < 0.01$). The correlations were slightly weaker between CXCR4 and GS ($R^2 = 0.3648, p = 0.0287$), EAAT1 and GS ($R^2 = 0.4377, p = 0.0076$), respectively in MPM samples, CXCL12 was not correlated with GS ($R^2 = 0.2879, p = 0.0886$) in MPM samples. As shown in Table 4, CXCL12, CXCR4, EAAT1 and GS have no strong correlations with each other in normal pleura samples. In addition, the positive staining areas of CXCL12, CXCR4, EAAT1 and GS were similar in some of other mesothelioma tissue samples.

**Table 3. Results of multiple correlation analysis of MPM samples**

|         | CXCL12 staining | CXCR4 staining | EAAT1 staining | GS staining |
|---------|-----------------|----------------|----------------|-------------|
| CXCL12  | $R^2 = 0.8590$, $p < 0.01$ | $R^2 = 0.6409$, $p < 0.01$ | $R^2 = 0.2879$, $p = 0.0886$ | --- |
|         | ---             |                |                |             |
### Results of multiple correlation analysis of normal pleura samples

|                  | CXCL12 | CXCR4 | EAAT1 | GS staining |
|------------------|--------|-------|-------|-------------|
| **CXCL12 staining** |        |       |       |             |
| R² = 0.6099      | R² = 0.0386 | R² = -0.2196 |
| p = 0.0611       | p = 0.9157    | p = 0.5421    |
| **CXCR4 staining** |        |       |       |             |
| R² = 0.5873      | R² = 0.2615 |
| p = 0.0742       | p = 0.4656    |
| **EAAT1 staining** |        |       |       |             |
| R² = 0.6262      |             |
| p = 0.0527       |             |
| **GS staining**  |        |       |       |             |
| ---               |             |       |       |             |

---: no data or not done.

### 2.2. The effects of CXCL12 on the CXCR4, EAAT1 and GS expression

In order to determine an optimal time point for the CXCL12 stimulation, H2052 cells were treated with various times (0 - 24 h) of CXCL12. Exposure to CXCL12 obviously increased the protein expression levels of CXCR4, EAAT1 and GS in a time dependent
manner and all three proteins reached their highest peak in 24 h (Figure 2A). Meanwhile, QPCR was also performed to detect their expressions at the transcriptional level. Similarly, as shown in Figure 3A, treatments of H2052 cells with CXCL12 increased the mRNA levels of CXCR4, EAAT1 and GS in a time dependent manner and all three genes reached their highest peak in 24 h.

**Figure 2.** Effects of CXCL12 on the levels of CXCR4, EAAT1 and GS protein in MPM cell line. (A), H2052 cells were incubated in the presence of CXCL12 (100 ng/mL) for various times (0 – 24 h) and subsequently the cells were lysed and the CXCR4, EAAT1 and GS were detected by western blot. (B), H2052 cells were transfected with CXCR4-RNAi or EAAT1-RNAi or respective controls and then treated with CXCL12 (100 ng/mL) for 24 h. The cells were lysed and the CXCR4, EAAT1 and GS were detected by western blot. 1: Control. 2: CXCL12. 3: CXCL12+CXCR4-RNAi. 4: CXCR4-RNAi. 5: CXCR4-RNAi control. 6: CXCL12+EAAT1-RNAi. 7: EAAT1-RNAi. 8: EAAT1-RNAi control. (C), H2052 cells were pretreated with AMD3100 (1.11 µM) or TFB (25 nM) for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h. The CXCR4, EAAT1 and GS were then determined by western blot. 1: Control. 2: CXCL12. 3: CXCL12+AMD3100. 4:
AMD3100. 5: Control. 6: CXCL12. 7: CXCL12+TFB. 8: TFB. The GAPDH was used as a control to ensure the same loading volume. The data shown were representative of three experiments, and the right panel of each example denoted the densitometry relative to GAPDH.

To explore the potential regulatory effects of CXCL12/CXCR4 axis on EAAT1/GS. First, we included four double-strands of candidate short interfering (siRNA) oligonucleotide sequences (siRNA#1, #2, #3 and #4) specific for CXCR4 and EAAT1 (Table S2) and then transiently transfected H2052 cells using CXCR4 or EAAT1 siRNA, respectively for 48 h. The results showed that CXCR4 or EAAT was knockdowned by CXCR4 siRNA#2 or EAAT siRNA#1 with the best inhibitory effect, respectively (Figure S1). Therefore, CXCR4 siRNA#2 and EAAT siRNA#1 were selected for the future experiments.

Next, H2052 cells were transfected with CXCR4 siRNA or EAAT siRNA alone, in the presence or absence of CXCL12 treatments or vehicle. As shown in Figure 2B, CXCR4 and EAAT1 silencing apparently suppressed CXCL12-upregulated the levels of EAAT1 and GS proteins. CXCR4 and EAAT1 silencing alone also obviously decreased the expression levels of both EAAT1 and GS proteins compared to control siRNAs, respectively. While, EAAT1 silencing slightly inhibited CXCL12-upregulated the expression of CXCR4, but failed to decrease the CXCR4 protein level compared to control siRNA. These findings suggest that EAAT1 locates downstream of CXCR4 and GS locates downstream of EAAT1. CXCL12 upregulates the expression of EAAT1 and GS proteins via CXCR4, and CXCL12 upregulates GS protein via EAAT1. In addition, to further confirm this finding, H2052 cells were treated with the CXCL12, AMD3100 and TFB alone, AMD3100 or TFB followed by CXCL12. The results were similar to the effects of CXCR4 and CXCL12 silencing. While, AMD3100 or TFB alone fail to decrease the protein levels of CXCR4, EAAT1 and GS compared with the control groups, respectively (Figure 2C). Similarly, as shown in Figure 3B, QPCR results showed that TFB obviously inhibited CXCL12-increased the expression of CXCR4, EAAT1 and GS mRNA.
Figure 3. Effects of CXCL12 on the levels of CXCR4, EAAT1 and GS mRNA in MPM cell line. (A), H2052 cells were incubated in the presence of CXCL12 (100 ng/mL) for various times (0 – 24 h) and the levels of CXCR4, EAAT1 and GS mRNA were detected by QPCR. (B), H2052 cells were pretreated with TFB for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h. The levels of CXCR4, EAAT1 and GS mRNA were then determined by QPCR. Values were expressed as fold of untreated control levels. * p < 0.05, ** p < 0.01 versus control. # p < 0.05 versus CXCL12 treatment, as indicated. The experiment data were expressed as mean ± SD from triplicates/quadruplicates and repeated three times independently.

2.3. The effects of CXCL12 on cell invasion and migration

The transwell assay was carried out to determine the effects of CXCL12 on the cell invasion and migration. Exposure to various concentrations of CXCL12 (0 - 100 ng/mL) promoted the invasion (Figure 4A) and migration (Figure 5A) in H2052 cells in a dose-dependent manner and both of them reached their highest peak in 100 ng/mL. In addition,
MTT was also performed to evaluate the cell proliferation. As shown in Figure S2A and S2B, CXCL12 (0 - 100 ng/mL) gradually promoted the proliferation in H2052 cells. AMD3100 (0 - 10 µM) gradually inhibited the proliferation in H2052 cells (Figure S2C).

Figure 4. Effects of CXCL12 on the invasion in MPM cell line. (A), H2052 cells were treated with various concentrations of CXCL12 (0 - 100 ng/mL) for 24 h and subsequently the cells invasion were evaluated by transwell assay. Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. (B), H2052 cells were transfected with CXCR4-RNAi or EAAT1-RNAi or respective controls and then treated with CXCL12 (100 ng/mL) for 24 h. The cells invasion were evaluated by transwell assay. 1: Control. 2: CXCL12. 3: CXCL12+CXCR4-RNAi. 4: CXCR4-RNAi. 5: CXCR4-RNAi control. 6: CXCL12+EAAT1-RNAi. 7: EAAT1-RNAi. 8: EAAT1-RNAi control. Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. (C), H2052 cells were pretreated with AMD3100 for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h. The cells invasion were evaluated by transwell assay.
Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. * p < 0.05, ** p < 0.01 versus control. # p < 0.05 versus CXCL12 treatment, as indicated. The data were expressed as mean ± SD from repeated three independent experiments.

To further define the effects of CXCR4 and EAAT1 on the cell invasion and migration, H2052 cells were transfected with CXCR4 siRNA or EAAT siRNA alone, in the presence or absence of CXCL12 treatments or vehicle. The results showed that CXCR4 siRNA or EAAT1 siRNA significantly suppressed CXCL12-promoted the H2052 cells invasion. CXCR4 siRNA or EAAT1 siRNA alone also slightly inhibited H2052 cells invasion (Figure 4B). Similar effects were also observed in H2052 cells migration (Figure 5B). Furthermore, H2052 cells were treated with the CXCL12, AMD3100 alone, AMD3100 followed by CXCL12. The results showed that CXCL12-promoted the cells invasion remarkably suppressed by AMD3100 (Figure 4C). Similar effects were also observed in H2052 cells migration (Figure 5C). These results indicated that CXCL12 regulated the invasion and migration also through CXCR4/EAA1 pathway in H2052 cells.
Figure 5. Effects of CXCL12 on the migration in MPM cell line. (A), H2052 cells were treated with various concentrations of CXCL12 (0 - 100 ng/mL) for 24 h and subsequently the cells migration were examined by transwell assay. Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. (B), H2052 cells were transfected with CXCR4-RNAi or EAAT1-RNAi or respective controls and then treated with CXCL12 (100 ng/mL) for 24 h. The cells invasion were examined by transwell assay. 1: Control. 2: CXCL12. 3: CXCL12+CXCR4-RNAi. 4: CXCR4-RNAi. 5: CXCR4-RNAi control. 6: CXCL12+EAAT1-RNAi. 7: EAAT1-RNAi. 8: EAAT1-RNAi control. Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. (C), H2052 cells were pretreated with AMD3100 for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h. The cells invasion were examined by transwell assay. Representative images from different groups were shown in left panel and the corresponding quantitative analysis was also presented in right panel. * p < 0.05, ** p <
0.01 versus control. # p < 0.05, ## p < 0.01 versus CXCL12 treatment, as indicated. The data were expressed as mean ± SD from repeated three independent experiments.

In addition, wound healing assay in vitro was also performed to assess the cell migration ability. H2052 cells were treated with the indicated agents for 24 h and 48 h. As shown in Figure S3A and S3B, the results were consistent with H2052 cells invasion and migration by transwell assay.

2.4. QPCR for MMP9

As is known to all, MMPs are frequently expressed in nearly all tumors, where they accelerates tumor progression. Among these MMPs, MMP9 is particularly known to play an important role in tumor progression, including tumor angiogenesis and growth as well as metastasis to distant organs [45,46]. Therefore, we focused on MMP9 and detected its expression in H2052 cells invasion. The result showed that CXCL12 slightly promoted the MMP9 mRNA level in 5 min (Figure S4). Moreover, H2052 cells were transfected with CXCR4 siRNA or EAAT siRNA alone, in the presence or absence of CXCL12 treatments or vehicle. As shown in Figure 6A, the CXCL12 significantly increased the MMP9 mRNA level in 24 h, while this effect was obviously suppressed by CXCR4 siRNA or EAAT1 siRNA. CXCR4 siRNA or EAAT1 siRNA alone also decreased the MMP9 mRNA level, respectively. Similarly, AMD3100 also inhibited CXCL12 - increased the MMP9 mRNA level (Figure 6B). All these data indicates that MMP9 is involved in the cell invasion.
Figure 6. Effect of CXCL12 on the MMP9 mRNA level in MPM cell line. (A), H2052 cells were transfected with CXCR4-RNAi or EAAT1-RNAi or respective controls and then treated with CXCL12 (100 ng/mL) for 24 h and the MMP9 mRNA was determined by QPCR. 1: Control. 2: CXCL12. 3: CXCL12+CXCR4-RNAi. 4: CXCR4-RNAi. 5: CXCR4-RNAi control. 6: CXCL12+EAAT1-RNAi. 7: EAAT1-RNAi. 8: EAAT1-RNAi control. (B), H2052 cells were pretreated with AMD3100 for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h. The MMP9 mRNA was then determined by QPCR. Values were expressed as fold of untreated control levels. * p < 0.05, ** p < 0.01 versus control. * # p < 0.05, ## p < 0.01 versus CXCL12 treatment, as indicated. The data shown were representative of three independent experiments.

2.5. In vivo experiments

Two weeks after inoculation, the tumors were obviously visible on more than half of the mice’s back (Figure S5A). The mice were excluded and not counted if no tumor could be visible on the mice back. The final number of each group was six (n = 6). The tumor
sizes of all four groups increased. Fluorescence signal (Figure S5B) was enhanced from 2 weeks to 5 weeks in all groups. The changes of fluorescence signal values from four groups in 1 week, 2 weeks and 3 weeks after the treatments were shown in Table S3. The changes of fluorescence signal values had no significant difference between four groups in 1 week and 2 weeks. After 3 weeks of treatment, the changes of fluorescence signal values from each treatment group were remarkably different from the control group (Table S4, p < 0.05). Compared with control group, CXCL12 promoted the growth of H2052 cells in nude mice, both AMD3100 and TFB inhibited the growth of H2052 cells in nude mice.

3. Discussion

Chemokines are thought to play a critical role in tumor growth, invasion and progression [47]. Previous studies have showed that there is obvious correlation between multiple chemokine receptors in many kinds of human malignant tumor metastases, including gastric carcinoma [48], T-cell leukemia [49], osteosarcoma [50], colorectal cancer [51,52], hepatocellular carcinoma [53], ovarian cancer [54], malignant melanoma [55,56], and renal cell carcinoma [57]. Our previous studies [43,44] indicated that both chemokines (CXCL12/CXCR4) and Glu system (EAAT1/GS) were involved in MPM tumorigenesis. In the present study, we found that CXCL12, CXCR4, EAAT1 and GS staining were more positive in MPM samples than that of in normal pleura samples. These results indicated that CXCL12, CXCR4, EAAT1 and GS were highly expressed in MPM samples. According to the multiple correlation analysis, CXCL12, CXCR4, EAAT1 and GS had strong correlations with each other in MPM samples except between CXCL12 and GS. In normal pleura samples, there were no strong correlations between them according to p values, but there were weaker correlations between them according to $R^2$ values. This difference may be due to the limited sample sizes.

In order to explore the potential regulatory effects of CXCL12/CXCR4 axis on EAAT1/GS. We performed siRNA knockdown and specific antagonists blocking experiments. Our results for the first time demonstrated that CXCL12 upregulated the
expression of EAAT1 and GS via CXCR4, and CXCL12 upregulated the expression of GS protein via EAAT1. CXCR4 silencing alone decreased the expression levels of EAAT1 and GS proteins compared to control siRNA, but conversely, EAAT1 silencing alone failed to decrease the CXCR4 protein level compared to control siRNA, which indicates that EAAT1 is a downstream factor of CXCR4 and GS is a downstream factor of EAAT1. It is noticeable that according to our results (Figure 2B), EAAT1 silencing conversely slightly inhibited CXCL12-upregulated the expression of CXCR4. This suggests that one possible mutual regulatory relationship exists between them. However, the impact of CXCR4 on EAAT1 is greater than that of EAAT1 on CXCR4.

Many recent studies reported that CXCL12/CXCR4 axis induces cell proliferation, invasion and migration, including cancer cells, such as human gastric cancer [58], endometrial cancer [59], epithelial ovarian cancer [60], cervical cancer [61], ovarian cancer [62], breast cancer [63], adamantinomatous craniopharyngiomas [64] and non-cancer cells, such as osteoblast [65], fibroblasts [66] and bone marrow stem cells [67]. In the present study, we also investigated the roles of CXCL12/CXCR4 axis in MPM cells proliferation, invasion and migration. Our results from Figure 4, 5 and 6 and Figure S2, S3 and S4 showed that CXCL12/CXCR4 axis promoted proliferation, invasion and migration in MPM cells, which were consistent with those previous results. Additionally, we detected the invasion-associated protease, such as MMP9, which was involved in cells invasion. Moreover, to assess the role of EAAT1 in invasion and migration of MPM cells, we used specific EAAT1 siRNA to knockdown the EAAT1 expression and found that CXCL12-promoted the H2052 cells invasion and migration were significantly suppressed by EAAT1 silencing, and to a certain extent, EAAT1 silencing alone also inhibited H2052 cells invasion and migration. Besides, CXCL12-increased the expression of MMP9 mRNA was remarkably inhibited by EAAT1 silencing. These results denoted that CXCL12 regulated the invasion and migration also through CXCR4/EAAT1/GS pathway in H2052 cells.

Our recent study showed that AMD3100 could inhibit the growth of MPM in vivo [68]. In this study, the results showed that CXCL12 promoted the growth of MPM in vivo. AMD3100 also inhibited the growth of MPM in vivo, which was consistent with our...
previous report. This indicates that the progression of MPM is associated with CXCL12/CXCR4. Besides, in vivo results showed that TFB treatment also inhibited the growth of MPM in vivo. All these results suggested that CXCL12/EAA1 may be another axis that affects the cell proliferation, invasion and migration in MPM cells. The CXCL12 binding the CXCR4 receptor activated divergent signals on multiple pathways, such as ERK1/2, p38, SAPK/JNK, AKT, mTOR [17], which reminds us that CXCL12/EAA1 axis proposed also may activate certain signaling pathway molecules in cancer cell, and thus represents a potential target for cancer treatment.

In sum up, Although we obtained the first evidence that EAA1 is a downstream factor of CXCR4 and GS is a downstream factor of EAA1. CXCL12 regulated the invasion and migration through CXCR4/EAA1/GS pathway in H2052 cells. There are still some limitation in our research, for example, CXCL12/CXCL4- or CXCL12/EAA1-mediated downstream signaling pathways involved in cell invasion and migration needs further study. Therefore, our next research will attempt to explore the molecular signaling pathways and mechanisms involved. It will bring us a deeper insights of clinical significance and provide us with many potential candidate targets and theoretical basis for drug development.

4. Materials and Methods

4.1. Reagents, drugs and antibodies

RNA extraction reagent and real-time quantitative PCR (QPCR) kit were purchased from Invitrogen (Carlsbad, CA, USA). Reverse transcriptional system (First Strand cDNA Synthesis Kit) was purchased from Promega (Medison, WI, USA). Fetal bovine serum (FBS), RPMI 1640 medium and phosphate buffer saline (PBS) were from Gibco (Carlsbad, CA, USA). Trypsin was purchased from Life Technologies (Waltham, MA, USA). Human CXCL12 was purchased from Upstate (Lake Placid, NY, USA). AMD3100 and TFB-TBOA (TFB) were purchased from Sigma (St. Louis, MO, USA). Matrigel and Propidium
Iodide (PI) were obtained from BD Pharmingen (Franklin Lakes, NJ, USA). Transwell chambers were purchased from Corning Costar (Corning, NY, USA).

4.2. Cell culture

Human malignant pleural mesothelioma (MPM) cell line H2052 was purchased from the Cell Culture Core Facility at Harvard University (Boston, MA, USA). The H2052 cells had been transfected with luciferase reporter gene and could stably express luciferase activity. The H2052 cells were maintained and cultured in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100 IU/ml) and streptomycin (100 μg/ml) and incubated at 37 °C with humidified air containing 5% CO₂.

4.3. Immunohistochemistry (IHC) staining

The tissue samples from 41 patients diagnosed with MPM were fixed in formalin and embedded in paraffin in 4-μm tissue microarray sections, which contained normal pleura tissue samples from another three patients. After routine processing, the sections were incubated with corresponding primary anti-CXCR4 (R&D Systems, Minneapolis, MN, USA), anti-CXCL12 (R&D Systems, Minneapolis, MN, USA), anti-EAAT1 (Cambridge, UK) or anti-GS antibody (Cambridge, UK), respectively, and then followed by routine immunostaining progress with the commercial kit (Maixin Biotechnology, Fuzhou, China) according to the manufacturer’s instructions. The IHC, HE staining procedures and the scoring system were carried out referring to our previous study [43].

4.4. Western blot

The H2052 cells in 6-well culture plates were washed three times with cold PBS and directly lysed with lysis buffer (Pierce, Rockford, IL, USA). The lysates were then centrifuged at 4°C, 15,000 rpm, for 15 min. Protein concentration was quantified using the Bradford reagent (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Equal amounts of total protein were resolved by standard 4 ~ 15% sodium
dodecyl sulfate polyacrylamide gels electrophoresis (SDS-PAGE), and then transferred to a nitrocellulose membranes (0.45 μm, Millipore Millex, USA). Membranes were blocked with 5% non-fat milk for 1 hour at room temperature, then washed with TBST and incubated overnight at 4°C with appropriate primary anti-CXCR4 (Abcam, Cambridge, UK), anti-glutamine synthetase (GS) (Abcam, Cambridge, UK), anti-EAAT1 (CST, Danvers, MA, USA) and anti-GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) antibody (CST, Danvers, MA, USA) at the dilution recommended. The membranes were washed with TBST to remove the primary antibodies and then incubated for 1 hour with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody IgG (Santa Cruz, CA, USA). GAPDH was used as a loading control. The protein bands were detected by SuperSignal west Femto (Thermo, Rockford, IL, USA) and Chemilumager 5500 (Alpha Innotech, Santa Clara, CA, USA).

4.5. RNA isolation and real-time PCR (QPCR)

Total RNA was extracted from the H2052 cells by TRIzol Reagent (Invitrogen, Carlsbad, CA). cDNA was reverse transcribed from total RNA by First Strand cDNA Synthesis Kit (Promega, Medison, WI) according to the manufacturer’s instructions. QPCR was carried out with the QPCR kit (Invitrogen, Carlsbad, CA) with the cDNA as a template. According to the protocol, cocktails (2X Real-Time SYBR PCR Master Mix, Template cDNA, Forward and Reverse primer pairs and Nuclease-Free water) were incubated at 50°C for 2 min and then denatured at 95°C for 10 min followed by 40 cycles at 95°C for 15 s, and then 1 min of final extension at 60°C. PCR for GAPDH was used as a control for RNA quantity. The ABI7500 real-time PCR system was performed to determine the mRNA expression. The forward and reverse primer pairs of CXCL12, CXCR4, GS, EAAT1, MMP9 and GAPDH were shown in Table S1.

4.6. Cell invasion and migration

Transwell chambers were dipped in 500 μL (1:100) Matrigel for 5 min, dried in the air, and inserted in 24-well flat-bottom plates overnight, then 200 μl invasion buffer was
added into the each well. The H2052 cells were serum-starved for 12 h, harvested, washed, resuspended in invasion buffer, and the density was adjusted to \(5 \times 10^5\) cell/mL with RPMI 1640 media. The invasion buffer of the upper Transwell chamber was abandoned carefully. 600 µl medium containing 1% FBS was added into the lower chamber. Subsequently, 100 µL of cell suspension was added into the upper chamber carefully to bestrew the cells on the filter. The cells were subjected to various treatments as indicated in figure. And then, the Transwell chambers were incubated in 37°C and 5% CO\(_2\) for 24 h. The transwell membrane of upper chamber was collected and the matrigel was removed by cotton tips. After fixation with methanol and staining with 0.1% crystal violet, the number of the invaded cells were counted randomly under a microscopy in 5 fields of visions (200 × magnification). For cell migration, no Matrigel is needed and the experimental procedures are the same with cell invasion assay.

4.7. Statistical analysis

Statistical analysis was carried out with SPSS 21.0 (SPSS Inc, Chicago, USA). Data were expressed as mean ± S.D. Student’s t-test or one way ANOVA was used to detect the differences between different groups. For correlation analysis, 0, 1, 2 and 3 represented -, +, ++ and +++, respectively during the calculation. P < 0.05 was considered to be of significance.

5. Conclusions

CXCL12 regulated the invasion and migration through CXCR4/EAA1/GS pathway in H2052 cells.

6. Patents

Fresh primary human MPM samples from 41 patients were obtained (the patients diagnosed with MPM underwent surgical removal of the primary tumor). The normal pleura tissue samples were obtained simultaneously to serve as controls from seven of these patients. We
confirmed that we had the informed consents from all patients and all tissue samples were analyzed complying with procedures approved by the institutional review board of the University of California, San Francisco (IRB H8714-22942-01) and Capital Medical University, Beijing.

Supplementary Materials

![Western blot analysis](image)

**Figure S1.** Western blot analysis was performed to validate the transfection effects of respective siRNA. H2052 cells were transfected with negative control siRNA or siRNA targeted to CXCR4 and EAAT1, respectively. Both the targeted CXCR4 and EAAT1 were downregulated. 1, 2, 3, 4 represents siRNA1, siRNA2, siRNA3, siRNA4 targeted to CXCR4 and EAAT1, respectively.
**Figure S2.** Effect of CXCL12 on the viability in MPM cell line. H2052 cells were treated with various concentrations of CXCL12 (0 - 100 ng/mL) (A) or AMD3100 (0 - 10 µM) (C) for 24 h and morphological images in vitro from different treatment groups were shown. (B). The cell viability was evaluated by MTT assay. * p < 0.05 versus control, as indicated. The data were expressed as mean ± SD from quadruplicates and repeated three times independently.
**Figure S3.** Effects of CXCL12 on the migration in MPM cell line. (A), H2052 cells were treated with various concentrations of CXCL12 (0 - 100 ng/mL) for 24 h, 48 h and subsequently the cells migration were examined by wound healing assay. Representative images (upper panel) and the corresponding quantitative analysis (lower panel) from different groups were shown. (C), H2052 cells were pretreated with AMD3100 for 30 min and then treated with CXCL12 (100 ng/mL) for 24 h and 48 h. The cells migration were examined by wound healing assay. Representative images (upper panel) and the corresponding quantitative analysis (lower panel) from different groups were presented. Values were expressed as relative migration distance (relative ratio of different treatment groups to untreated control). *p < 0.05 versus control. #p < 0.05 versus CXCL12 treatment, as indicated. The data were expressed as mean ± SD from repeated three independent experiments.

![Graph](image)

**Figure S4.** Effect of CXCL12 on the MMP9 mRNA level in MPM cell line. H2052 cells were treated with or without CXCL12 (100 ng/mL) for 5 min and the MMP9 mRNA was determined by QPCR. Values were expressed as fold of untreated control levels. The data shown were representative of three independent experiments.
Figure S5. Effect of CXCL12 on tumor growth in nude mice. 2 × 10^6 H2052 cells were inoculated subcutaneously (S.C.) into the left dorsal of nude mice, and the mice were treated with AMD3100, TFB, CXCL12 or vehicle starting 2 weeks after implantation, as described in Materials and methods. Obvious tumor appearance and (A) and bioluminescence/fluorescence signal value (B) could be visible on the mouse back.

Table S1. Primer pairs of CXCR4, GS, EAAT1, MMP9 and GAPDH

| Target gene | Primer pairs |
|-------------|--------------|
|             | Forward primer (5’ - 3’) | Reverse primer (5’ - 3’) |
| CXCR4       | TCAGTCTGGACCAGCTACCTG | GGGATCCAGACGCAAACATA |
| GS          | CAATCGAAGGCCTGCAGAGA | ATACTCTGCTCCATGCCAA |
| EAAT1       | TTGCTGCAAGCACTTCATCAC | GCTTGCCACGCCATTTGTC |
| MMP9        | TGTACCGCTATGGTTACACTCAG | GGCAGGGACAGTTGCTTCT |
| GAPDH       | CTTCTTTTGGTACGCAAGC | GGCAGCCCAATACGACCAAA |
Table S2. CXCR4 and EAAT1 siRNA oligonucleotide sequences

| Gene      | SiRNA oligos (5’-3’) | Sense                      | Anti-sense                  |
|-----------|----------------------|----------------------------|----------------------------|
| CXCR4(1)  | GGCUGAAAAGGUUGUGCUAUT | AUAGACCACCUUUCAGC          | CTT                        |
|           | T                    |                            |                            |
| CXCR4(2)  | GCCUUAUCAAUUGGGAUCT   | GAUCCCCAUGUAAGG            | CTT                        |
|           | T                    |                            |                            |
| CXCR4(3)  | CAAGCAAGGGUGUGAGUUUT  | AAACUCACACCUUUCUU          | GTT                        |
|           | T                    |                            |                            |
| CXCR4(4)  | GCACAAGUGGAUUUCCAUCT  | GAUGGAAAUCACUUGUG           | CTT                        |
|           | T                    |                            |                            |
| CXCR      | ACCAGGUUAUUGCAGUACGT  | CGUACUGCAUAACCUGG          |                            |
| Control   | T                    |                            | UTT                        |
| EAAT1(1)  | CGGGGAUAUAUCAGAUGT    | CAUCUGUAUAUUCCCG           | GTT                        |
|           | T                    |                            |                            |
| EAAT1(2)  | CCAUAACCAGCUAUACCUUT  | AAGGUUAGCGGUGGUAUG          | GTT                        |
|           | T                    |                            |                            |
| EAAT1(3)  | CCAAGAAGAAAGUGCAGAAT  | UUCUGCACUUUUCUUG           | GTT                        |
|           | T                    |                            |                            |
| EAAT1(4)  | CACUGAAGUGCAAGAAGAT   | UCUUCUUUGCACUUCAGU          | GTT                        |
|           | T                    |                            |                            |
| EAAT1     | ACCAGGUUAUUGCAGUACGT  | CGUACUGCAUAACCUGG          |                            |
| Control   | T                    |                            | UTT                        |

Table S3. The changes of fluorescence signal values of four groups

| After starting of treatments | Control | CXCL12 | AMD3100 | TFB    |
|------------------------------|---------|--------|---------|--------|
| 1 week                       | 0.98 ± 1.46 | 1.31 ± 1.31 | -0.16 ± 0.97 | 0.75 ± 1.23 |
2 weeks  2.80 ± 3.20  58.44 ± 63.82  2.13 ± 3.50  3.82 ± 3.24
3 weeks  6.89 ± 3.26  43.00 ± 36.58  0.97 ± 0.82  2.35 ± 2.49

Table S4. p values between groups at 3 weeks after starting of treatments

|     | AMD3100 | Control | CXCL12 | TFB   |
|-----|---------|---------|--------|-------|
| AMD3100 | P = 0.0021 | P = 0.0002 | P > 0.05 |       |
| Control   | P = 0.0368 |        | P = 0.0157 |       |
| CXCL12    |          |        | P = 0.0014 |       |
| TFB       |          |        |         |       |

**Author Contributions**

Shuo Li, Tong Li and Qiang Lin: Conceptualization, Methodology, Software; Shuo Li, Tong Li and Qiang Lin: formal analysis; Debing Shi, Shengcai Hou, Orli Kadoch, Yilin Yang and Zhidong Xu: resources; Shuo Li, Tong Li, Qiang Lin and Debing Shi: Data curation; Shuo Li, Tong Li and Qiang Lin: Writing- Original draft preparation; Tong Li: Visualization; Shuo Li, Tong Li, Qiang Lin, Debing Shi, Haishi Zheng, Jin Zhang and Hui Li: Investigation; Tong Li: Supervision, Tong Li: Validation, Tong Li: Writing- Reviewing and Editing, Tong Li: project administration, Tong Li: funding acquisition

**Funding**

This work was funded by a grant from the Beijing Natural Science Foundation Program, PRC (7152059 to Tong Li).

**Acknowledgments**

We are grateful for the support from the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation, Inc., the Estate of Robert Griffiths, the Jeffrey and Karen Peterson Family Foundation, Paul and Michelle Zygielbaum, the Estate of Norman Mancini, and the Barbara Isackson Lung Cancer Research Fund. We thank Kaiyue Zhang and Jianjun Zhou for their important directions in genes expressions and analysis.
We also thank Yi-Lin Yang from the Department of Surgery in UCSF for editorial assistance with the manuscript.

Conflicts of Interest

The authors declare no conflict of interest and the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Lagniau S, Lamote K, van Meerbeeck JP, Vermaelen KY: Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? Oncotarget (2017) 8(32):53751-53762.

2. Papaspyros S, Papaspyros S: Surgical management of malignant pleural mesothelioma: Impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies. ISRN Surg (2014) 2014(817203).

3. Zhang W, Wu X, Wu L, Zhang W, Zhao X: Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med (2015) 3(13):182.

4. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M et al: Bap1 regulates ip3r3-mediated ca(2+) flux to mitochondria suppressing cell transformation. Nature (2017) 546(7659):549-553.

5. Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G et al: Germline bap1 mutations induce a warburg effect. Cell Death Differ (2017) 24(10):1694-1704.

6. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D et al: Comprehensive
genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. *Nat Genet* (2016) **48**(4):407-416.

7. Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A et al: High-density array-cgh with targeted ngs unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. *Proc Natl Acad Sci U S A* (2016) **113**(47):13432-13437.

8. Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M et al: A subset of mesotheliomas with improved survival occurring in carriers of bap1 and other germline mutations. *J Clin Oncol* (2018) JCO2018790352.

9. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M et al: Consensus report of the 2015 weinman international conference on mesothelioma. *J Thorac Oncol* (2016) **11**(8):1246-1262.

10. Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, Corradi M: Microrna expression in malignant pleural mesothelioma and asbestosis: A pilot study. *Dis Markers* (2017) **2017**(9645940.

11. Napolitano A, Carbone M: Malignant mesothelioma: Time to translate? *Trends Cancer* (2016) **2**(9):467-474.

12. Tan Y, Sementino E, Chernoff J, Testa JR: Targeting myc sensitizes malignant mesothelioma cells to pak blockage-induced cytotoxicity. *Am J Cancer Res* (2017) **7**(8):1724-1737.

13. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A et al: International union of basic and clinical pharmacology. [corrected]. Lxxix. Update on the extended family of chemokine receptors and introducing a new
nomenclature for atypical chemokine receptors. *Pharmacol Rev* (2014) 66(1):1-79.

14. Van Hout A, D’Huys T, Oeyen M, Schols D, Van Loy T: Comparison of cell-based assays for the identification and evaluation of competitive cxc-r4 inhibitors. *PLoS One* (2017) 12(4):e0176057.

15. Aversa I, Zolea F, Ierano C, Bulotta S, Trotta AM, Faniello MC, De Marco C, Malanga D, Biamonte F, Viglietto G, Cuda G et al: Epithelial-to-mesenchymal transition in fhc-silenced cells: The role of cxc-r4/cxcl12 axis. *J Exp Clin Cancer Res* (2017) 36(1):104.

16. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Litman DR: Function of the chemokine receptor cxc-r4 in haematopoiesis and in cerebellar development. *Nature* (1998) 393(6685):595-599.

17. Scala S: Molecular pathways: Targeting the cxc-r4-cxcl12 axis—untapped potential in the tumor microenvironment. *Clin Cancer Res* (2015) 21(19):4278-4285.

18. Bajetto A, Barbieri F, Pattarozzi A, Dorcaratto A, Porcile C, Ravetti JL, Zona G, Spaziante R, Schettini G, Florio T: Cxcr4 and sdf1 expression in human meningiomas: A proliferative role in tumoral meningothelial cells in vitro. *Neuro Oncol* (2007) 9(1):3-11.

19. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N: Stromal cell-derived factor-1 and cxc-r4 receptor interaction in tumor growth and metastasis of breast cancer. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* (2006) 60(6):273-276.

20. Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Tomita S, Ichikawa K, Imura J, Hiraishi H, Fujimori T: Expression of sdf-1 alpha and nuclear cxc-r4 predicts lymph node metastasis in colorectal cancer. *British journal of cancer* (2008) 98(10):1682-1689.
21. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL et al: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410(6824):50-56.

22. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G: Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood (2002) 99(8):2703-2711.

23. Rollins BJ: Chemokines. Blood (1997) 90(3):909-928.

24. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM: A review on cxcr4/cxcl12 axis in oncology: No place to hide. Eur J Cancer (2013) 49(1):219-230.

25. Lombardi L, Tavano F, Morelli F, Latiano TP, Di Sebastian P, Maiello E: Chemokine receptor cxcr4: Role in gastrointestinal cancer. Crit Rev Oncol Hematol (2013) 88(3):696-705.

26. Barbieri F, Bajetto A, Stumm R, Pattarozzi A, Porcile C, Zona G, Dorcaratto A, Ravetti JL, Minuto F, Spaziante R, Schettini G et al: Overexpression of stromal cell-derived factor 1 and its receptor cxcr4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res (2008) 14(16):5022-5032.

27. Burger JA, Kipps TJ: Cxcr4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2006) 107(5):1761-1767.

28. Lau BW, Kane AB: Sdf1/cxcl12 is involved in recruitment of stem-like progenitor cells to orthotopic murine malignant mesothelioma spheroids. Anticancer Res (2010) 30(6):2153-2160.

29. Shimizu Y, Dobashi K, Imai H, Sunaga N, Ono A, Sano T, Hikino T, Shimizu K, Tanaka S, Ishizuka T, Utsugi M et al: Cxcr4+foxp3+cd25+ lymphocytes accumulate in cxcl12-expressing malignant pleural mesothelioma. Int J Immunopathol Pharmacol (2009) 22(1):43-51.

30. Mayer ML, Westbrook GL: The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol (1987) 28(3):197-276.
31. Kalariti N, Pissimissis N, Koutsilieris M: The glutamatergic system outside the CNS and in cancer biology. *Expert opinion on investigational drugs* (2005) 14(12):1487-1496.

32. Billups B, Rossi D, Oshima T, Warr O, Takahashi M, Sarantis M, Szatkowski M, Attwell D: Physiological and pathological operation of glutamate transporters. *Prog Brain Res* (1998) 116(45-57).

33. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A: Muller cells in the healthy and diseased retina. *Prog Retin Eye Res* (2006) 25(4):397-424.

34. Schousboe A, Westergaard N, Waagepetersen HS, Larsson OM, Bakken IJ, Sonnewald U: Trafficking between glia and neurons of tca cycle intermediates and related metabolites. *Glia* (1997) 21(1):99-105.

35. Danbolt NC: Glutamate uptake. *Prog Neurobiol* (2001) 65(1):1-105.

36. John BJ, Irukulla S, Abulafi AM, Kumar D, Mendall MA: Systematic review: Adipose tissue, obesity and gastrointestinal diseases. *Alimentary pharmacology & therapeutics* (2006) 23(11):1511-1523.

37. Barbour B, Keller BU, Llano I, Marty A: Prolonged presence of glutamate during excitatory synaptic transmission to cerebellar Purkinje cells. *Neuron* (1994) 12(6):1331-1343.

38. Diamond JS, Jahr CE: Transporters buffer synaptically released glutamate on a submillisecond time scale. *J Neurosci* (1997) 17(12):4672-4687.

39. Mennerick S, Zorumski CF: Glial contributions to excitatory neurotransmission in cultured hippocampal cells. *Nature* (1994) 368(6466):59-62.

40. Nguyen TV, Li J, Lu CJ, Mamrosh JL, Lu G, Cathers BE, Deshaies RJ: P97/vcp promotes degradation of crbn substrate glutamine synthetase and neosubstrates. *Proc Natl Acad Sci USA* (2017) 114(14):3565-3571.

41. Eisenberg D, Gill HS, Pfuegl GM, Rotstein SH: Structure-function relationships of glutamine synthetases. *Biochim Biophys Acta* (2000) 1477(1-2):122-145.
42. Martinez-Hernandez A, Bell KP, Norenberg MD: Glutamine synthetase: Glial localization in brain. *Science (New York, NY) (1977) 195*(4284):1356-1358.

43. Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, Jablons DM, You L: The expression of cxcr4, cxcl12 and cxcr7 in malignant pleural mesothelioma. *The Journal of pathology* (2011) **223**(4):519-530.

44. Li T, Hou SC, Mao JH, Wang YC, Lu XD, Tan JL, You B, Liu YP, Ni J, Au A, Jablons DM et al: The expression of dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma. *J Clin Pathol* (2012) **65**(9):855-858.

45. Bendrik C, Robertson J, Gauldie J, Dabrosin C: Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. *Cancer research* (2008) **68**(9):3405-3412.

46. Jespersen C, Doller A, Akool el S, Bachmann M, Muller R, Gutwein P, Muhl H, Pfelschifter J, Eberhardt W: Molecular mechanisms of nitric oxide-dependent inhibition of tpa-induced matrix metalloproteinase-9 (mmp-9) in mcf-7 cells. *Journal of cellular physiology* (2009) **219**(2):276-287.

47. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. *Cancer science* (2007) **98**(11):1652-1658.

48. Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H, Mori M: Expression of chemokine receptor ccr7 is associated with lymph node metastasis of gastric carcinoma. *Cancer Res* (2002) **62**(10):2937-2941.

49. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shinizu S, Ito M, Komatsu H, Wakita A et al: Clinical significance of ccr4 expression in adult t-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. *Clin Cancer Res* (2003) **9**(10 Pt 1):3625-3634.

50. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Hvos AG, Healey JH, Gorlick R: Messenger rna expression levels of cxcr4 correlate with
metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 11(7):2561-2567.

51. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS: Chemokine receptor cxcr4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 23(12):2744-2753.

52. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M: Effect of chemokine receptors cxcr4 and ccr7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res (2005) 11(5):1743-1750.

53. Uchida H, Iwashita Y, Sasaki A, Shibata K, Matsumoto T, Ohta M, Kitano S: Chemokine receptor ccr6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol (2006) 21(1 Pt 1):161-168.

54. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR: Expression of chemokine cxcl12 and its receptor cxcr4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol (2006) 103(1):226-233.

55. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A: Cxcr3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: Correlation with clinicopathological prognostic factors. J Clin Pathol (2007) 60(6):596-599.

56. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G: Expression of cxcr4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 11(5):1835-1841.

57. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Beldegrun AS, Pantuck AJ: The chemokine receptor cxcr3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol (2008) 179(1):61-66.
58. Xiao J, Lai H, Wei SH, Ye ZS, Gong FS, Chen LC: Lncrna hotair promotes gastric cancer proliferation and metastasis via targeting mir-126 to active cxcr4 and rhoa signaling pathway. *Cancer Med* (2019) 8(15):6768-6779.

59. Liu P, Long P, Huang Y, Sun F, Wang Z: Cxcl12/cxcr4 axis induces proliferation and invasion in human endometrial cancer. *Am J Transl Res* (2016) 8(4):1719-1729.

60. Mao TL, Fan KF, Liu CL: Targeting the cxcr4/cxcl12 axis in treating epithelial ovarian cancer. *Gene Ther* (2017) 24(10):621-629.

61. Wang C, Cheng H, Li Y: Role of sdf-1 and cxcr4 in the proliferation, migration and invasion of cervical cancer. *Pak J Pharm Sci* (2016) 29(6 Spec):2151-2154.

62. Guo Q, Gao BL, Zhang XJ, Liu GC, Xu F, Fan QY, Zhang SJ, Yang B, Wu XH: Cxcl12-cxcr4 axis promotes proliferation, migration, invasion, and metastasis of ovarian cancer. *Oncol Res* (2014) 22(5-6):247-258.

63. Guo S, Xiao D, Liu H, Zheng X, Liu L, Liu S: Interfering with cxcr4 expression inhibits proliferation, adhesion and migration of breast cancer mda-mb-231 cells. *Oncol Lett* (2014) 8(4):1557-1562.

64. Yin X, Liu Z, Zhu P, Wang Y, Ren Q, Chen H, Xu J: Cxcl12/cxcr4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via pi3k/akt signal pathway. *J Cell Biochem* (2019) 120(6):9724-9736.

65. Wang J, Zhao B, Yang S, Wang D, Xu H, Teng M: Scutellarin enhances osteoblast proliferation and function via nf-kappab-mediated cxcr4 induction. *Gene* (2018) 676(29-36).

66. He C, Li D, Gao J, Li J, Liu Z, Xu W: Inhibition of cxcr4 inhibits the proliferation and osteogenic potential of fibroblasts from ankylosing spondylitis via the wnt/betacatenin pathway. *Mol Med Rep* (2019) 19(4):3237-3246.
67. Zhang H, Jiang C, Li M, Wang X, Tian F, Fang X, Zhu L, Bian Z: Cxcr4 enhances invasion and proliferation of bone marrow stem cells via pi3k/akt/nf-kappab signaling pathway. *Int J Clin Exp Pathol* (2017) **10**(9):9829-9836.

68. Li J, Li T, Li S, Xie L, Yang YL, Lin Q, Kadoch O, Li H, Hou S, Xu Z: Experimental study of the inhibition effect of cxcl12/cxcr4 in malignant pleural mesothelioma. *J Investig Med* (2019) **67**(2):338-345.